Core Viewpoint - Changchun High-tech, a leading company in the growth hormone industry, is experiencing a significant decline in net profit, with a forecasted drop of 91.48% to 94.19% for 2025 compared to the previous year [1] Group 1: Financial Performance - In the third quarter of 2025, Changchun High-tech reported a revenue of 9.807 billion yuan, a decrease of 5.6% year-on-year, and a net profit of 1.165 billion yuan, down 58.23% year-on-year [1] - The peak net profit for Changchun High-tech was 4.532 billion yuan in 2023, but it fell by 43% in 2024, indicating a continuing downward trend into 2025 [1] - The company anticipates a net profit of 150 million to 200 million yuan for 2025, marking a substantial decline from previous years [1] Group 2: Market and Product Dynamics - The sales of growth hormones are influenced by the number of adolescents and newborns, with increased competition also impacting performance [2] - Changchun High-tech's long-acting growth hormone and related products have been included in the new national medical insurance directory, effective January 1, 2026, with a price reduction of approximately 75% [2] - The company has adjusted its sales policies and pricing in response to industry policy changes and market conditions, which has contributed to reduced revenue and net profit [2] Group 3: Subsidiary Performance - Changchun High-tech's subsidiary, Baike Biological, is expected to report a net loss of 220 million to 280 million yuan for 2025, marking its first loss since going public, primarily due to intensified competition and decreased vaccination willingness [3] - The sales revenue of the shingles vaccine from Baike Biological has already seen a decline of 71.54% in 2024, continuing to be negatively affected in 2025 [4] - Factors affecting the shingles vaccine sales include public awareness of the disease, vaccination willingness, and increased market competition, leading to unsold inventory and returns [4]

Core Insights - The new national medical insurance drug list was officially implemented on January 1, adding 114 new drugs, including long-acting growth hormones for children with endogenous growth hormone deficiency [1] Group 1: Drug Inclusion and Benefits - Two domestic long-acting growth hormone preparations included in the insurance are Yipei (from TeBao Biotech) and Jinpei (from JinSai Pharmaceutical), with Yipei being a class 1 new drug expected to launch in 2025 [2] - Long-acting growth hormones require administration only once a week, significantly reducing the number of injections by over 300 per year compared to traditional short-acting hormones, thus improving adherence and long-term management [2] Group 2: Price Adjustments - The price of Yipei 5mg was reduced from 1798 yuan to 853.2 yuan, a decrease of approximately 53%, while Jinpei's price was reported to drop from about 3500 yuan to approximately 900 yuan, a reduction of about 75% [2] - The actual price for Jinpei may vary as it still requires negotiations with local insurance bureaus, and the reported price of 900 yuan is considered an industry secret [2] Group 3: Financial Impact on Patients - For a child weighing 30 kg, the annual treatment cost with Jinpei was estimated to drop from about 120,000 yuan to 30,000 yuan after the price reduction, with potential further reductions based on local insurance reimbursement policies [5] - Families previously facing high treatment costs due to ineffective therapies will experience substantial relief from the new pricing structure [5]

Group 1 - The recent inclusion of long-acting growth hormone in the national medical insurance directory is expected to significantly reduce treatment costs for families, with prices dropping from approximately 4000-5000 yuan per month to around 2000 yuan after January 2026 [1][2] - Two long-acting growth hormone products, namely Yipei and Jinsai, have been included in the national medical insurance directory, with Yipei's price reduced by about 53% from 1798 yuan to 853.2 yuan, and Jinsai's price reduced by approximately 75% from 3500 yuan to around 900 yuan [2][3] - The annual treatment cost for patients with growth hormone deficiency is projected to decrease from about 120,000 yuan to 30,000 yuan after the price reduction, with further reductions possible through local insurance reimbursements [2][3] Group 2 - The growth hormone market in China has rapidly expanded, with the market size increasing from 4 billion yuan in 2018 to 12 billion yuan in 2022, making China the largest market globally for growth hormone [7][8] - The competitive landscape is evolving, with multiple companies, including Jinsai and Yipei, as well as new entrants like Anke Bio and Tianjing Bio, actively developing long-acting growth hormone products [8][9] - The approval of international long-acting growth hormone products, such as Novo Nordisk's product, is expected to intensify competition in the domestic market [8][9]

Core Viewpoint - Changchun High-tech (000661) has seen its stock price decline by 0.53% to 99.2 yuan, with a total market capitalization of 40.467 billion yuan as of December 8, 2025. The company announced that two of its products have been included in the National Medical Insurance Directory, which is expected to enhance their market potential and revenue streams [1]. Group 1 - Changchun High-tech's stock opened at 100.07 yuan, reached a high of 100.45 yuan, and a low of 99.02 yuan on the same day, with a trading volume of 5.43 billion yuan and a turnover rate of 1.37% [1]. - The company’s subsidiary, Jinsai Pharmaceutical, has received approval for its self-developed product, Jin Pei Sheng Growth Hormone Injection (brand name: Jin Sai Zeng), and the co-introduced product, Acetate Medroxyprogesterone Oral Suspension (brand name: Mei Shi Ya), to be included in the National Medical Insurance Directory [1]. - Jin Pei Sheng is specifically indicated for children with growth retardation due to endogenous growth hormone deficiency, while Mei Shi Ya is indicated for weight loss in AIDS patients with anorexia and cachexia [1]. Group 2 - The reimbursement standards for these newly included drugs will be effective from January 1, 2026, to December 31, 2027, with the new directory set to be implemented starting January 1, 2026 [1].